报价延迟最少15分钟:2026/08/02 00:36 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.49 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.64/0.83
|
|
企业价值
349.47M
|
| 资产负债 |
|
每股账面净值
3.45
|
| 现金流量 |
|
现金流量率
0.08
|
| 损益表 |
|
收益
95.02M
|
|
每股收益
1.03
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US. |
